Niramai Health Analytix, a Deeptech health startup raised research funding from impact investor CDC for NIRAMAI FeverTest, which was launched last year.
With leveraging of computer vision and AI to analyze and monitor crowd compliance to COVID-19 guidelines, NIRAMAI FeverTest’s smart software enables screening for COVID-19 symptoms in public places.
This company’s COVID-19 screening tech helps screen for symptoms like fever and respiratory illness at entrances to hospitals, educational institutions, workplaces, residential communities, and other public places.
Srini Nagarajan, Managing Director, South Asia at CDC Group, a UK-based finance institution said, “Tracking and controlling rapid community spread of the virus remains a key challenge. NIRAMAI FeverTest is a technology that will amplify the efforts to save lives, preserve public safety, and reduce the economic impact of the pandemic in India. Its innovative solutions will complement the national response to combating COVID-19 and we are pleased that the technology can support India in meeting the challenge head-on, bolstering the country’s steps toward bringing the pandemic under control.”
In partnership with South Western Railways, two major railway stations of Bengaluru are using this technology at their entrances. This tech helps police personnel of the Railway Protection Force seamlessly scan thousands of commuters for compliance with COVID-19 protective measures.
“The financial support from CDC has enabled us to successfully pilot our AI-enabled COVID screening product at IT tech parks, schools and some hospitals across Indian cities,” Geetha Manjunath, Founder and CEO of NIRAMAI stated in a release.
NIRAMAI is a pioneer in developing thermal-imaging-based and AI-based breast cancer screening solutions. Being backed by Pi Ventures, this startup’s cloud-hosted analytics solution uses artificial intelligence, big data analytics, and machine learning algorithms for early breast cancer screening.
Niramai has recently launched a home-based screening service for breast cancer at home in June 2020 to quickly detect and assist the patient with a female technician within 48 hours of booking an appointment.
